O Berk pharma bottle is ready to ship

Published: 27-May-2010

HDPE Pharma Oblong in amber now available from stock

O Berk pharma bottle is ready to ship
O Berk Company, a US supplier and distributor of glass and plastic containers, closures, pumps and sprayers for the pharmaceutical and healthcare industries, is offering its 16oz HDPE Pharma Oblong bottle in amber from stock. The bottle is also available by special order in natural, white or a custom colour.

The 16oz Pharma Oblong is suitable for prescription and over-the-counter (OTC) liquid pharmaceutical products. There bottle is supplied with a variety of child-resistant and standard continuous threaded closures. The bottle surface has an indented panel that is easy to personalise.

Both bottles and closures are supported with data indicating US FDA compliance.

See more

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Distribution
Closing the gap between strategy and resilience in pharmaceutical supply chains

Closing the gap between strategy and resilience in pharmaceutical supply chains

Read more
Pharmaceutical manufacturers must align technology, operations and visibility to build resilient supply chains amid shortages, rising costs and geopolitical instability

Trending Articles

  1. Johnson & Johnson to spend up to $750m restructuring pharmaceutical supply chain The pharma giant is consolidating parts of its manufacturing network as it advances a $55bn US investment programme aimed at expanding domestic production of advanced medicines
  2. Grünenthal joins genetic medicine cluster CNATM to advance RNA therapeutics The pain specialist has joined the Cluster for Nucleic Acid Therapeutics Munich to strengthen its oligonucleotide drug discovery capabilities and accelerate the development of genetic medicines for neurological diseases
  3. Brabender TwinLab B-TSE-S 30/40: Pilot-scale extrusion with lab-level insight With throughput up to 100 kg/h, the new twin-screw extruder brings lab-grade process understanding into pilot-scale production, enabling users to validate process parameters and produce relevant quantities under realistic conditions
  4. Manufacturing Chemist Stand Side with GEA and Hovione We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  5. Sativex approved in Sweden For the treatment of spasticity due to multiple sclerosis

Upcoming event

CPhI Milan

6–8 October 2026 | Exhibition | Fiera Milano, Italy See all

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Distribution
Closing the gap between strategy and resilience in pharmaceutical supply chains

Closing the gap between strategy and resilience in pharmaceutical supply chains

Pharmaceutical manufacturers must align technology, operations and visibility to build resilient supply chains amid shortages, rising costs and geopolitical instability
Sustainability
Gerresheimer commissions photovoltaic system in Pfreimd

Gerresheimer commissions photovoltaic system in Pfreimd

Approximately 500,000 kWh of solar power annually from own rooftops | Expansion of the share of renewable energy at the site
Analysis
New chemisorption analyser redefines catalyst characterisation

New chemisorption analyser redefines catalyst characterisation

Anton Paar introduces the Autosorb 3300: Advanced flow chemisorption analysis with unprecedented ease of use and automation
Research & Development
Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Mission Therapeutics divests acute kidney injury drug MTX652 in $292m Dimerix deal

Cambridge-based biotech Mission Therapeutics has divested its Phase II-ready USP30 inhibitor MTX652 to renal specialist Dimerix in a deal worth up to $292m, allowing the company to accelerate its Parkinson’s disease pipeline
Pharma 5.0
FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

FPT launches MediSight AI framework to accelerate pharma digital transformation and regulatory compliance

The new AI-powered platform combines autonomous digital workers, interoperable healthcare data and compliance tools to help pharmaceutical manufacturers, medical device companies and healthcare providers scale AI adoption
Regulatory
Early phase analytical strategy for biosimilars in a shifting regulatory landscape

Early phase analytical strategy for biosimilars in a shifting regulatory landscape

As FDA and EMA guidance continues to reinforce analytical comparability as the foundation of biosimilar development, investing in comprehensive early-stage characterisation is becoming essential to reduce uncertainty and improve development outcomes, says Dr Andrew J. Reason, CEO at BioPharmaSpec
Manufacturing
Vacuubrand Vario® chemistry diaphragm pumps

Vacuubrand Vario® chemistry diaphragm pumps

The ideal solution for your laboratory
Subscribe now